Abstract
Percutaneous coronary angioplasty started a revolution by providing a mechanical means of relieving angina. Abrupt vessel closure and restenosis emerged as its major limitations. Bare-metal stents dramatically reduced acute vessel closure, but restenosis, although significantly reduced, remained a clinical problem. Drug-eluting stents mitigated the problem of restenosis to a large extent. However, a small but significant increase in very-late stent thrombosis rates have been noted. Newer stents have been introduced in order to improve the efficacy and safety of stent implantation. The everolimus-eluting Xience V™ stent has been extensively evaluated in the SPIRIT clinical trial program. This article summarizes the various studies of this program and their impact on clinical practice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
